Browsing by Author "Loriot, Yohann"

Sort by: Order: Results:

  • Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
    Powles, Thomas; Sridhar, Srikala S.; Loriot, Yohann; Bellmunt Molins, Joaquim, 1959-; Mu, Xinmeng Jasmine; Ching, Keith A.; Pu, Jie; Sternberg, Cora N.; Petrylak, Daniel P.; Tambaro, Rosa; Dourthe, Louis M.; Alvarez-Fernandez, Carlos; Aarts, Maureen; Di Pietro, Alessandra; Grivas, Petros; Davis, Craig B. (Nature Research, 2021)
    In a recent phase 3 randomized trial of 700 patients with advanced urothelial cancer (JAVELIN Bladder 100; NCT02603432 ), avelumab/best supportive care (BSC) significantly prolonged overall survival relative to BSC alone ...
  • Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    Powles, Thomas; Bellmunt Molins, Joaquim, 1959-; Comperat, E.; De Santis, Maria; Huddart, R.; Loriot, Yohann; Necchi, Andrea; Valderrama, B.P.; Ravaud, A.; Shariat, S.F.; Szabados, B.; van der Heijden, M.S.; Gillessen, S.; ESMO Guidelines Committee (Elsevier, 2022)
    Disclosure TP has received research funding from Merck Serono, Merck, Sharp & Dohme (MSD), Roche, Bristol Myers Squibb (BMS), AstraZeneca, Astellas, Novartis, Johnson and Johnson, Seattle Genetics, Pfizer, Exelixis and ...
  • Prognostic value of the lung immune prognosis index score for patients treated with immune checkpoint inhibitors for advanced or metastatic urinary tract carcinoma
    Parent, Pauline; Auclin, Edouard; Patrikidou, Anna; Mezquita, Laura; Martínez Chanzá, Nieves; Dumont, Clement; Rodriguez-Vida, Alejo; Llacer, Casilda; Lozano, Rebeca; Ratta, Raffaele; Merseburger, Axel S.; Sternberg, Cora N.; Baciarello, Giulia; Colomba, Emeline; Fuerea, Alina; Besse, Benjamin; Loriot, Yohann; Lavaud, Pernelle (MDPI, 2023)
    Few prognostic factors have been identified in patients with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs). The Lung Immune Prognostic Index (LIPI) was associated with clinical ...
  • Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial
    Pal, Sumanta; Somford, Diederik M.; Grivas, Petros; Sridhar, Srikala S.; Gupta, Shilpa; Bellmunt Molins, Joaquim, 1959-; Sonpavde, Guru; Fleming, Mark T.; Lerner, Seth Paul; Loriot, Yohann; Hoffman-Censits, Jean; Valderrama, Begoña P.; Andresen, Corina; Schnabel, Marco J.; Cole, Suzanne; Daneshmand, Siamak (Future Medicine, 2022)
    PROOF 302 is an ongoing randomized, double-blind, placebo-controlled, adjuvant phase III trial (NCT04197986) in approximately 218 patients from 120 centers worldwide. Eligibility criteria include post-surgical high-risk ...
  • Treatments outcomes in histological variants and non-urothelial bladder cancer: results of a multicenter retrospective study
    Epaillard, Nicolas; Parent, Pauline; Loriot, Yohann; Lavaud, Pernelle; Vera-Cea, E-B; Martinez-Chanza, Nieves; Rodriguez-Vida, Alejo; Dumont, Clement; Lozano, Rebeca; Llácer, Casilda; Ratta, Raffaele; Oudard, Stephane; Thibault, Constance; Auclin, Edouard (Frontiers, 2021)
    Introduction: Less than one-third of bladder cancers are non-pure urothelial carcinoma [with variant histological (VH) or non-urothelial carcinoma (non-UC)] for which no treatment guidelines are available. We aim to evaluate ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking